Saturday 17 October 2026
Export OCUL’s income statement to Excel — free account
Ocular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 10.3%, free cash flow fell 25.4% and total debt rose 4.13%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.87
0.51
−6.91%
Follow OCUL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
2 | 4 | 3 | 3 |
| (81.83%) | (54.85%) | (68.55%) | (72.99%) | ||
| (55.41%) | (42.01%) | (51.03%) | (53.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(70.40%) | (35.41%) | (42.93%) | (49.04%) | |
Average Days of Receivables |
201.32 | 215.34 | 170.77 | 212.19 | |
Free Cash Flow per Share |
(1.08) | (1.16) | (1.07) | (1.13) | |
Free Cash Flow |
(199.31) | (216.76) | (240.81) | (255.10) | |
Capital Expenditures |
(9.24) | (11.88) | (14.61) | (16.86) | |
| Other line items | |||||
Cash ROIC |
(29.59%) | (14.82%) | (18.24%) | (21.41%) | |
Accounts Receivable Turnover |
1.83 | 1.65 | 2.10 | 1.72 | |
Accounts Payable Turnover |
1.21 | 1.58 | 1.05 | 1.04 | |
Inventory Turnover |
2.11 | 1.99 | 1.90 | 1.95 | |
Average Days of Payables |
367.94 | 230.64 | 441.12 | 380.67 | |
Days of Inventory on Hand |
205.01 | 197.88 | 205.39 | 208.18 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
335.73% | 379.39% | 423.64% | 429.38% | |
Selling, General and Administrative Expense of Revenue |
202.78% | 227.71% | 239.03% | 260.78% | |
Share Based Compensation of Revenue |
69.95% | 83.12% | 92.84% | 102.36% | |
Interest Coverage |
(20.72) | (22.82) | (25.75) | (27.53) | |
Operating CF/Net income |
0.76 | 0.77 | 0.78 | 0.79 | |
Depreciation/Fixed assets |
0.24 | 0.22 | 0.25 | 0.28 | |
Capex/Depreciation |
(2.30) | (2.75) | (3.16) | (3.09) | |
Revenue per Share |
0.30 | 0.28 | 0.23 | 0.23 | |
Operating CF per Share |
(1.03) | (1.09) | (1.01) | (1.06) | |
Capex per Share |
(0.05) | (0.06) | (0.07) | (0.07) | |
Capex to Sales |
0.17 | 0.23 | 0.28 | 0.32 |
Columns are period end dates